A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

NCT00906373 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)
BIOLOGICAL: IMC-A12 (cixutumumab) - 20 mg/kg
DRUG: Sorafenib

Sponsor

Eli Lilly and Company